Pooled analysis showed that low/negative expression of TYMS was associated with a significant progression free survival benefit in advanced NSCLC patients treated with pemetrexed-based chemotherapy (HR 0.50, 95%CI [0.41, 0.61] P<0.00001; Figure 4). Here, TYMS is linked to non-small cell lung carcinoma.